Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
NuCana. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
NuCana's earnings available for a low price, and how does
this compare to other companies in the same industry?
NuCana's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
Unable to determine if NuCana is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
NuCana's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Hugh S. Griffith is a Co-Founder of NuCana BioMed Limited and has been its Chief Executive Officer since March 2008. Mr. Griffith is also the Chief Executive Officer at Alida Capital International Ltd. He is an Advisor to the Saltire Foundation. He served as the Chief Operating Officer of Bioenvision Ltd. since July 2004. He served as the Chief Operating Officer of Bioenvision Inc. since July 2004. He has held numerous positions in Abbott Laboratories; Parke-Davis, Warner Lambert and QuantaNova Ltd. He served as a Commercial Director (Europe) of Bioenvision Ltd. from October 2002 to July 2004. From January 2002 to October 2002, he served as an Executive Commercial Director of QuantaNova Ltd. From January 2000 to December 2001, he served as a Senior Business Unit Manager at Abbott Laboratories Ltd., where he was responsible for strategic development, implementation and commercialization of a new neonatology business unit. From April 1998 to January 2000, Mr. Griffith served as the HIV Business Unit Manager at Abbott Laboratories Ltd. where he was responsible for the profitability of the HIV franchise. He managed the Norvir capsule crisis including the fully comprehensive named patient programme. At Abbott Laboratories Ltd., he also served as a Business Development Manager from July 1997 to April 1998 and as an Area Sales Manager from October 1995 to July 1997. He has been a Director of NuCana BioMed Limited since March 2008. He serves as a Partnership Board Member at Deepbridge Capital LLP. Mr. Griffith also serves on the Angel Leaders Forum, Scottish Lifesciences Association, LiSAB technology and capital workstreams. He supports a number of early stage biopharmaceutical companies as co-founder, Director, investor and/or advisor. He is a senior executive with two decades experience in the biopharmaceutical industry, having held Chief Executive Officer , Chief Operating Officer and Executive Director positions. He has wide pharmaceutical experience. Mr. Griffith holds a Masters of Business Administration from Cardiff Business School, a Diploma of Marketing and a Bachelor of Science in Honours Biology from University of Stirling.
Hugh's compensation has increased whilst company is loss making.
Hugh's remuneration is about average for companies of similar size in Germany.
Chairman & Chief Medical Officer
Chief Financial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the NuCana board of directors is about average.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.